SYS-CON MEDIA Authors: RealWire News Distribution, Cynthia Dunlop, Mark O'Neill, Kevin Benedict

News Feed Item

Masimo Brings High Technology Medical Equipment to India

Expands Presence With Advanced Noninvasive Patient Monitoring

BANGALORE, INDIA and IRVINE, CA -- (Marketwired) -- 01/06/14 -- Masimo (NASDAQ: MASI), the inventor of breakthrough noninvasive patient monitoring technologies, today announced the opening of offices across India to meet the health demands of the burgeoning Indian market.

Masimo, a successful, publicly traded medical technology company employing more than 3,000 people worldwide with product revenues that have steadily increased in the last five years, has technology license and OEM agreements with leading patient monitoring manufacturers spanning the globe, including Atom, Datascope, GE Medical, Medtronic, Philips, Spacelabs, and Zoll.

"We have found that India is an important market for several reasons -- the most important is that the penetration of high technology devices is very low, a factor that could lead to thousands of avoidable instances of death and illness. As a leader in noninvasive patient monitoring, including measure through motion and low perfusion pulse oximetry, Masimo's technologies will be able to make a significant impact to improve patient safety and outcomes," said Jon Coleman, President, Masimo Worldwide Sales, Professional Services and Medical Affairs.

Masimo is working with India's top medical and nursing practitioners to raise greater awareness of the clinical and cost challenges that Masimo's innovative technologies can solve, including:

  • Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry. Compared to other pulse oximeters during patient motion and low perfusion, Masimo SET® provides measurements when other pulse oximeters cannot, dramatically reduces false alarms (specificity), and accurately detects true alarms (sensitivity)(1,2) that can indicate a deteriorating patient. Most importantly, Masimo SET® pulse oximetry has been shown to improve patient outcomes by helping clinicians reduce retinopathy of prematurity (ROP)(3) in neonates, screen newborns for critical congenital heart disease (CCHD),(4,5) reduce ventilator weaning time and arterial blood gas measurements in the ICU,(6) and save lives and costs while reducing rapid response activations and intensive care unit transfers on the general floor.(2)
  • rainbow® Pulse CO-Oximetry™, which allows clinicians to noninvasively monitor multiple blood constituents, such as
  • Total hemoglobin (SpHb®), when used in conjunction with laboratory testing, SpHb monitoring can help clinicians reduce unnecessary blood transfusions in both low and high blood-loss surgery situations, and also helps initiate more timely transfusions when they are truly indicated(7,8);
  • Carboxyhemoglobin (SpCO®), shown to be useful as a first-line assessment tool in helping clinicians rapidly detect carbon monoxide (CO) poisoning(9);
  • Methemoglobin (SpMet®), shown to help clinicians assess for methemoglobinemia(10) -- a dangerous reaction to some hospital-administered drugs that reduces the delivery of oxygen to the tissues. Other breakthrough technologies include:
  • RAM™ acoustic respiration rate (RRa™), which noninvasively and continuously measures respiration rate using an innovative adhesive sensor with an integrated acoustic transducer that is easily and comfortably applied to the patient's neck, and shown to be as effective as capnography (nasal cannula) and better tolerated by patients(11);
  • Root™, a powerful new patient monitoring and connectivity platform that integrates breakthrough rainbow® and SET® measurements with multiple additional parameters -- including SedLine® brain function monitoring and Phasein™ capnography and gas monitoring.* Root includes a dock for the Radical-7® handheld Pulse CO-Oximeter and acoustic respiration rate monitor, an instantly interpretable display, and multiple networking/connectivity options. Root integrates multiple streams of data and simplifies patient care workflows, empowering caregivers to help make quicker patient assessments, earlier interventions, and better clinical decisions; and
  • Masimo Patient SafetyNet™, a remote monitoring and clinician notification system clinically shown to keep patients safer by enabling remote continuous monitoring of the patient's physiology, including oxygenation and pulse rate, which has led to saved lives, reductions in rapid response activations and transfers to intensive care units.(12)

Local response from the clinical community has been overwhelming.

"I've been using Masimo technology for the last three years or so and am very happy to hear about Masimo's commitment to the region," said Dr. Anil Karlekar, executive director and head of anesthesiology and critical care at Fortis Escorts Heart Institute in New Delhi. "I look forward to closer collaboration with the Masimo India team."

"I have found that Masimo's technology is best in picking up SpO2 in compromised babies, particularly when very sick," said Dr. Ashish Mehta of Arpan Nursing Home, in Ahemdabad, where he and his team focus on pre-term newborns and care for more than 600 babies a year. "I rely on this technology in my clinic and am very happy to learn that Masimo is now in India and better poised to serve its local clients."

"I'm glad to learn that Masimo has arrived in India through its own sales and clinical team," added Dr. Kartik Nagesh, head of neonatology at Manipal Hospital in Bangalore. "We have been using Masimo technology in our NICU for some years and now with a local presence we are more confident about our ability to improve quality of care to our neonatal patients."

1 Shah N, Ragaswamy HB, Govindugari K, Estanol L "Performance of Three New-Generation Pulse Oximeters during Motion and Low Perfusion in Volunteers".J Clin Anesth. 2012 Aug;24(5):385-91.
2 Taenzer, Andreas H.; Pyke, Joshua B.; McGrath, Susan P.; Blike, George T. "Impact of Pulse Oximetry Surveillance on Rescue Events and Intensive Care Unit Transfers: A Before-and-After Concurrence Study." Anesthesiology, February 2010, Vol. 112, Issue 2. Available online here.
3 Castillo A, et al. Acta Paediatr. 2011 Feb.;100(2):188-92.
4 de-Wahl Granelli A., et al. BMJ. 2009 Jan 8;338.
5 Ewer A, et al. Health Technol Assess. 2012;16(2):1-184.
6 Durbin, et al. Critical Care Medicine. 2002 Aug.;30(8): 1735 to 1740.
7 Ehrenfeld JM et al. ASA. 2010. LB05. (abstract)
8 Awada WNFM et al. Anesth Analg 2013; (117 suppl): 50 (abstract).
9 Sebbane M, Claret PG, Mercier G, Lefebvre S, Thery R, Dumont R, et al. "Emergency Department Management of Suspected Carbon Monoxide Poisoning: Role of Pulse Co-Oximetry." Respir Care. Published online ahead of print Mar 19, 2013. Available here
10 Annabi E.H., Barker S,J. Anesth Analg. 2009;108:898-9.
11 Patino M., Redford D.T., Quigley T.W., Mahmoud M., Kurth C.D., Szmuk P. Accuracy of acoustic respiration rate monitoring in pediatric patients. Pediatric Anesthesia. 2013 Sep 3.
12 Taenzer A, Blike G, McGrath S, Pyke J, Herrick M, Renaud C, Morgan J. "Postoperative Monitoring - The Dartmouth Experience." Anesthesia Patient Safety Foundation Newsletter Spring-Summer 2012. Available online
*Root is CE Marked

About Masimo
Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care -- helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies have shown that Masimo SET® outperforms other pulse oximetry technologies, even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow SET® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI). Additional information about Masimo and its products may be found at www.masimo.com.

Forward-Looking Statements
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our belief that Masimo SET provides real-time results for all patients to help clinicians to more rapidly assess, diagnose, and treat every patient; risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including: total hemoglobin (SpHb), SpCO, SpMet, and RRa contribute to positive clinical outcomes and patient safety; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI, rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57,Rad-8, Rad-5, Pulse CO-Oximetry, Pulse CO-Oximeter, Adaptive Threshold Alarm, and SeDLine are trademarks or registered trademarks of Masimo Corporation. The use of the trademarks Patient SafetyNet and PSN are under license from University HealthSystem Consortium.

Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2489601

Media Contacts:
Bharat Monteiro
Masimo Corporation
Phone: 1800-425-MASIMO (627466)
Email: info-india@masimo.com

Archana Muthappa (India)
Adfactors PR Pvt Ltd
91 44 42655800
archana.muthappa@adfactorspr.com

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.